Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis

BACKGROUND: Mechanisms of resistance have been described during disease progression (PD) for patients under treatment with anti-EGFR plus chemotherapy (CT). The aim of our study was to evaluate efficacy of anti-EGFR rechallenge (ReCH) and reintroduction (ReIn) in metastatic colorectal cancer (mCRC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Karani, Amanda, Felismino, Tiago Cordeiro, Diniz, Lara, Macedo, Mariana Petaccia, Silva, Virgilio Souza e, Mello, Celso Abdon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373642/
https://www.ncbi.nlm.nih.gov/pubmed/32728385
http://dx.doi.org/10.3332/ecancer.2020.1069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373642/
https://www.ncbi.nlm.nih.gov/pubmed/32728385
http://dx.doi.org/10.3332/ecancer.2020.1069

Ejemplares similares